Search
Future
You may find below an overview of the dates and locations of the future EHA Congresses.
For information on future congresses, please contact Connect at a. congress@ehaweb.
About us
The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.
Read moreHow to apply for CBTH
TimelinesApplication CBTH 2025
Deadline: September 24, 2024 (15:00 CEST)
Notification
November 2024
How to apply?Download the signature letter template. Fill in the template and get it duly signed for upload into the online application platform.
Practical information
Timelines:Application deadline: September 24, 2024 (15:00 CEST)
Notification of awards: December 2024
When & where do the meetings take place?Workshop 1:
Date: April 22-26, 2025
Venue: Cambridge, UK
CBTH session and EHA Congress:
Date: June 11-15, 2025
Venue: TBC
Workshop 2:
Date:…
Thrombocytopenias and Platelet Function Disorders
The SWG was established at the 2003 EHA Congress, which was held in Lyon, France. The group's original focus was thrombocytopenias, but it subsequently expanded its field of interest with the inclusion of platelet function disorders.
Read moreInfections in Hematology
The SWG on Infection in Hematology was founded in 2017 and follows four main goals:
Develop and share clinically useful tools: Many hematologists create checklists and pathways for quick and easy reference.
Quality of Life and Symptoms
The goals of the SWG are:
To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.
Chronic Myeloid Leukemia
The objective of this SWG is the cure of Chronic Myeloid Leukemia (CML) by cooperative research.
Read moreAcute Myeloid Leukemia
The AML SWG represents a group of national and internationally renowned clinical and research experts working in the field of AML.
Read moreAging and Hematology
The SWG "Aging and Hematology" has four main goals for the next four years (2019-2023):
To share clinically useful tools in assessing frailty and comorbidities in older adults with hematologic malignancies.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- »